We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
- Abstract
This article provides information on the use of pembrolizumab in the treatment of bladder and renal cancer, as well as new data on screening for prostate cancer. The study on bladder cancer found that patients who received enfortumab vedotin and pembrolizumab had longer progression-free survival and overall survival compared to those who received platinum-based therapy. The study on renal cancer showed that adjuvant pembrolizumab improved overall survival but had a higher risk of adverse events. Additionally, the article discusses the results of two randomized trials on PSA screening for prostate cancer, with one trial showing a lower prostate cancer mortality rate but a small absolute reduction in deaths.
- Subjects
RENAL cancer; PROSTATE cancer; BLADDER cancer; DATA integrity; PEMBROLIZUMAB; GLEASON grading system
- Publication
BJU International, 2024, Vol 134, Issue 1, p4
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.16429